Global marketing and registration of finished dosage forms
Breathing life into markets
We are your perfect partner for an early and global market entry!
We at TIEFENBACHER GROUP strongly believe that our high-quality medicines should be available and affordable for all patients – irrespective of their origin or income level. That´s why we always strive for a global and early market entry for our customers. Thanks to our high excellence and international knowledge in research & development and regulatory affairs, we have already obtained more than 15.000 marketing authorizations in over 80 markets worldwide.
While we master the complexity of country-specific regulatory requirements and maintain close contact to the relevant pharmaceutical authorities, our customers can focus on their important brand marketing and save time and money. Outstanding intellectual property guidance, a professional project management, and an efficient supply chain approach are further important drivers for our strong track record in generating first-to-file-dossiers.
Tiefenbacher market access at a glance
Our strong track record in marketing and registration speaks for us
TIEFENBACHER GROUP drives force for advanced medicines – all products are manufactured in full compliance with the principles of intellectual property (IP). We stand for reliability, the highest standards of safety and quality, and a forward-looking approach along the entire pharmaceutical value chain.
15.000+
MAs obtained
in80+
countries worldwide
150+
marketing partners on five continents
350+
tender awards in 12 months
15.000+
MAs obtained
in80+
countries worldwide
150+
marketing partners on five continents
350+
tender awards in 12 months
highly rated regulatory expertise
frequent first-to-file generic dossiers
first NCE approved
several US filings
highly rated regulatory expertise
frequent first-to-file generic dossiers
first NCE approved
several US filings
Our best-in-class medicines based on a patient-centered approach
TIEFENBACHER Group develops, manufactures, and commercializes generic, value-added, and innovative medicines for patients worldwide
Driven by our purpose of bringing high-quality medicines within affordable reach to patients around the world, we provide over 180+ products across various therapeutic categories in 10+ dosage forms – and additional medical devices. We are not limited to specific disease areas – whether for widespread or for orphan diseases. We are developing in-house products that address specific therapeutic needs in unique formulations of prescription drugs (Rx) as well as over-the-counter (OTC) medicines – for the benefit of patients worldwide. Furthermore, we are committed for growth and innovation by offering a well-defined and specialized portfolio of highly potent drugs.
Diseases Areas
Oncology
Respiratory
Neuroscience
Cardiovascular, Renal and Metabolism
Immunology, Hepatology and Dermatology
Infectious Diseases
Ophthalmology
Dosages Forms
Tablets
Capsule
Powder
Drops
Inhaler
Transdermal Patches
Eye drops
Additional
Medical Devices
Our global licensing approach
Global availability of our high-quality pharmaceuticals: marketing authorizations in 80+ countries
Dr. Kristian Ruepp
Managing Director
„Thanks to our international knowledge in R&D and regulatory affairs, we enable our customers to enter global markets as fast as possible – making our high-quality medicines more affordable and more available for patients worldwide."
TIEFENBACHER GROUP: Pioneering Healthcare
From initial idea to market access worldwide. Through our extensive experience and profound expertise in the international healthcare markets, we are making pharmaceuticals more affordable, more available, and better than before.For more information about our advanced medicines – our portfolio provides over 180+ products across various therapeutic categories in 10+ dosage forms – please contact us by filling out the contact form below and clicking “Send message”, or directly send an email to info@aet.eu. We, at TIEFENBACHER GROUP, will follow up with you personally as soon as possible.
Find out more on aet.eu
